George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImage Scan Holdings Regulatory News (IGE)

Share Price Information for Image Scan Holdings (IGE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.20
Bid: 1.10
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.20 (18.182%)
Open: 1.20
High: 1.20
Low: 1.20
Prev. Close: 1.20
IGE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

27 Apr 2022 07:00

RNS Number : 4361J
Image Scan Holdings PLC
27 April 2022
 

Image Scan Holdings plc

Interim Report 2022

27/04/2022

 

 

 

IMAGE SCAN HOLDINGS PLC

("Image Scan" or the "Company")

(AIM: IGE)

 

INTERIM RESULTS

 

Image Scan, (AIM: IGE) specialists in the field of X-ray imaging for the security and industrial inspection markets, today announces its interim results for the six months ended 31 March 2022. During the first six months the overall level of trading was disappointing, though some important new customers were acquired, and a significant new product was launched.

Financial summary:

· Order intake increased to £1,029k (H1 2021: £938k)

· Revenue was £790k (H1 2021: £868k)

· Gross profit margin of 52% (H1 2021: 55%)

· Loss before taxation of £345k (H1 2021: loss of £201k)

· Period end bank balance was £777k (H1 2021: £1.1m)

· Period end orderbook of £721k (H1 2021: £702k)

 

Operational highlights:

· New, highly integrated ThreatScan®-AS1 portable X-Ray system launched

· New portable X-ray orders from UK police forces

· First order from a US federal agency in the period

· New global customer for industrial X-ray systems

· All customer deadlines met despite global supply chain disruptions

As indicated in our trading update on 22 February 2022, while we expect the overall financial year to be stronger in H2 2022, it is unlikely H2 2022 will be sufficiently strong to enable the Company to fully recover the H1 2022 loss. We therefore expect to trade in line with market expectations for the year as a whole.

 

Bill Mawer, Chairman and Chief Executive Officer of Image Scan commented: "The overall level of trading in our first half is disappointing, an indication of the sluggish recovery of our markets from the impact of the COVID-19 pandemic. We consider the ThreatScan®-AS1 portable X-ray system to be our most significant product launch for some years. This project has aimed to develop the best performing portable X-ray system in the world and the initial customer response has been very positive. We look for a number of delayed government procurements for portable X-ray systems to finally close and are working hard to ensure this happens early in the second half. The slowdown in the automotive market is impacting our industrial activity, though the acquisition of a new customer in this space is a positive development."

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

For further information on the Company, please visit: www.ish.co.uk and for further information on its products, please visit: www.3dx-ray.com

 

Enquiries:

Image Scan Holdings plc

William Mawer, Executive Chairman

Sarah Atwell King, Finance Director and Company Secretary

Tel: +44 (0) 1509 817 400

ir@ish.co.uk

W H Ireland - Nominated Adviser and Broker

Mike Coe/Sarah Mather (Corporate Finance)

 

 

Tel: +44 (0) 207 220 1666

 

Chairman's statement

Introduction

Image Scan Holdings plc is a specialist in innovative X-ray technology, operating globally in the security and industrial inspection sectors. The Company's principal activity is the design, manufacture, and supply of both portable and fixed X-ray security screening systems to governments, security organisations and law enforcement agencies. The Company also supplies high-quality screening systems used in the manufacture of catalytic converters and diesel particulate filters.

 

Financial results

Order intake for the first six months ended 31 March 2022 ("H1 2022") increased by 10% to £1,029k (H1 2021: £938k) and included the acquisition of some significant new customers for both industrial and security systems. Revenues declined by 9% to £790k (H1 2021: £868k). Gross margin on those revenues was at 52% (H1 2021: 55%), the reduction in part due to increased costs for materials, components and shipping.

 

Operating expenses increased to £752k (H1 2021: £682k), reflecting the loss of government COVID-19 support schemes and higher expenditure on marketing and travel. The latter was driven by the re-opening of travel routes and the return of security trade shows, which provide an important showcase for the Company's products. The overall effect of reduced sales and margin, coupled with higher costs, led to a loss in H1 2022 of £345k (H1 2021: loss of £201k).

 

Stock increased to £581k (H1 2021: £366k). Part of this increases was driven by decisions to hold higher than normal quantities of parts, in particular electronic components, as a buffer against anticipated shortages and price increases. The process of amortising appropriate research and development spend, which began in FY 2021, led to an increase in non-current assets to £425k (H1 2021: £360k).

 

The Company finished H1 2022 with an orderbook of £721k (H1 2021: £702k) and positive cash balance of £777k (H1 2021: £1.1m).

 

 

Overview

As in the same period last year, the overall level of trading was disappointing, with delays to several significant overseas government procurements. However, our high-value ThreatScan®-LSC portable X-ray system, which combines large format and compact detector panels in a single package, is proving popular with UK police forces. We now have three customers in this sector. We have also received a portable X-Ray order from a US Federal agency and found new customers for the Axis-CXi cabinet X-ray system.

An important milestone in H1 2022 was the market launch of the new ThreatScan®-AS1 portable X-Ray system. This is the first time the Company has used amorphous silicon detector technology, which is the same technology used in the majority of medical X-ray systems. The new system is highly integrated, combining generator, detector panel, computer, touch-screen display, Wi-Fi unit and power supplies in a single rugged case. A second tablet computer adds further flexibility in the use of the system. In what has become a crowded market, this bold move by the Company aims to provide the best performing portable X-ray system in the world. Initial response from early demonstrations in the Middle East and the UK, has been positive. The system will be demonstrated at security trade shows in Singapore and North America in the next few months.

Development of the new Axis conveyor X-ray systems was delayed somewhat due to the focus on the ThreatScan®-AS1 which is now complete, and the system will be offered to customers in the second half of FY2022. Following signature of a distribution agreement, we added the Serstech range of portable chemical analysers to our product range and are now presenting these to our global customers and partners. We are also offering other third-party products to customer and distribution partners through our website.

In the industrial market, with the automotive industry heavily impacted by COVID-19, it is encouraging that the business was both able to gain a new customer and received follow-on orders from existing customers. All our industrial service contracts were maintained through the continuing pandemic, despite the difficulties arising from travel restrictions.

Global supply chains have been considerably disrupted by multiple factors and this is reflected in price inflation and shortages across multiple commodities and components. Transport costs have also increased dramatically. The Company has worked hard to isolate itself as far as possible from the effects of these trends. However, we have had to accept higher prices for scarce electronics components and have taken decisions to protect production schedules by holding higher stock levels of certain items than would be normal to ensure customer deliveries continue to be made on time.

Outlook

The pandemic continues to impact global trade and travel, and only recently has attendance at security trade shows and demonstrations to overseas customers restarted. This has been a far from ideal environment in which to launch our ambitious new portable X-ray system but, with additional demonstration units in production, promotion of this important system is a key focus for H2 2022. We look for a number of delayed government procurements for portable X-ray systems to finally close and are working hard to ensure this happens sufficiently quickly to impact second half sales for FY 2022.

The automotive sector will be slow to recover from COVID-19 and our business in this sector is likely to be impacted while our customers adjust their manufacturing footprint to reflect the magnitude and distribution of global demand for catalytic converters. This makes our success in winning a new customer even more important, and it is to be hoped that their trial of the first machine leads to the same type of global deployment carried out by our other industrial customers. We have now successfully imaged components for an automotive fuel cell manufacturer and will continue to explore opportunities in this area.

As indicated in our trading update on 22 February 2022, while we expect the overall financial year to be stronger in H2 2022, it is unlikely H2 2022 will be sufficiently strong to enable the Company to fully recover the H1 2022 loss. We therefore expect to trade in line with market expectations for the year as a whole.

 

 

Bill Mawer

Executive Chairman

27/04/2022

 

Consolidated income statement

For the six months ended 31 March 2022

 

Note

Six months

ended

31 March 2022

(Unaudited)

£'000

Six months

ended

31 March 2021

(Unaudited)

£'000

Year ended

30 September

 2021

(Audited)

£'000

Revenue

790

868

2,873

Cost of sales

(383)

(387)

(1,359)

Gross profit

407

481

1,514

Operating expenses

(752)

(682)

(1,325)

Operating (loss)/profit

(345)

(201)

189

Finance income

-

-

-

Loss/(profit) before taxation

(345)

(201)

189

Taxation

-

-

51

Loss/(profit) for the period

(345)

(201)

240

 

Pence

Pence

Pence

Earnings per share

Basic profit per share

[3]

(0.25)

(0.15)

0.18

Diluted profit per share

(0.25)

(0.15)

0.17

 

 

Consolidated statement of changes in equity

For the six months ended 31 March 2022

 

Note

Six months

ended

31 March 2022

(Unaudited)

£'000

Six months

ended

31 March 2021

(Unaudited)

£'000

Year ended

30 September

 2021

(Audited)

£'000

Opening equity shareholders' funds

1,649

1,409

1,409

Shares Issued

10

-

-

(Loss)/profit attributable to equity shareholders

(345)

(201)

240

Closing equity shareholders' funds

1,314

1,208

1,649

 

Consolidated statement of financial position

As at 31 March 2022

 

As at

31 March 2022

(Unaudited)

£'000

As at

31 March 2021

(Unaudited)

£'000

As at

30 September

 2021

(Audited)

£'000

Non-current assets

Intangible and tangible assets

425

61

360

425

61

360

Current assets

Inventories

581

366

393

Trade and other receivables

591

404

741

Cash and cash equivalents

777

1,048

1,186

1,949

1,818

2,320

Total assets

2,374

1,879

2,680

Current liabilities

Trade and other payables

874

671

836

Non-current liabilities

186

-

195

Total liabilities

1,060

671

1,031

Net assets

1,314

1,208

1,649

Equity

Share capital

1,368

1,363

1,363

Share premium account

8,333

8,328

8,328

Retained earnings

(8,387)

(8,483)

(8,042

Equity shareholders' funds

1,314

1,208

1,649

 

Consolidated cash flow statement

For the six months ended 31 March 2022

 

Six months

ended

31 March 2022

(Unaudited)

£'000

Six months ended 31 March 2021 (Unaudited) £'000

Year ended

30 September

 2021

(Audited)

£'000

Cash flows from operating activities

Operating (loss)/profit

(345)

(201)

189

Adjustments for:

Depreciation

7

10

8

Amortisation of Intangibles

12

-

19

Impairment of inventories

5

9

-

Amortisation of right of use asset

23

21

43

(Decrease)/increase in provision for warranty

(13)

(9)

12

(Increase)/decrease in inventories

(196)

75

57

Decrease/(increase) in trade and other receivables

148

(90)

(426)

Increase/(decrease) in trade and other payables

67

(98)

45

Lease Interest

(3)

-

4

Net cash used in operating activities

(295)

(283)

(49)

Corporation tax recovered

(5)

(1)

51

Net cash outflow from operating activities

(300)

(284)

2

Cash flows from investing activities

Interest received

-

-

-

Purchase of intangible and tangible assets

(103)

(7)

(130)

Net cash used in investing activities

(103)

(7)

(130)

Cash flows from financing activities

Share Issue

10

(Repayment)/proceeds from bank loan

-

(50)

(50)

Lease payments

(16)

(21)

(46)

Net cash used in financing activities

(6)

(71)

(96)

Net decrease in cash and cash equivalents

(409)

(362)

(224)

Cash and cash equivalents at beginning of period

1,186

1,410

1,410

Cash and cash equivalents at end of period

777

1,048

1,186

 

Notes to the unaudited interim financial statements

For the six months ended 31 March 2022

 

1 Basis of preparation

The interim financial statements, which are unaudited, have been prepared on the basis of the accounting policies expected to apply for the financial year to 30 September 2022 and in accordance with recognition and measurement principles of International Financial Reporting Standards ('IFRSs') as endorsed by the European Union. The accounting policies applied in the preparation of these interim financial statements are consistent with those used in the financial statements for the year ended 30 September 2021.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim financial reporting'. Accordingly, whilst the interim statements have been prepared in accordance with IFRSs, they cannot be construed as being in full compliance with IFRSs.

 

The financial information for the year ended 30 September 2021 does not constitute the full statutory accounts for that period. The annual report and financial statements for the year ended 30 September 2021 have been filed with the Registrar of Companies. The Independent auditor's report on the report and financial statements for the year ended 30 September 2021 was unqualified, did not draw attention to any matters by way of emphasis, and did not contain a statement under Section 498(2) or 498(3) of the Companies Act 2006.

 

2 Going concern

The interim financial information has been prepared on a going concern basis, which assumes that the Company will have adequate resources to continue in operational existence for the foreseeable future.

 

3 Earnings per share ('EPS')

Basic earnings per ordinary share is based on the loss on ordinary activities before taxation of £345k and on 136,854,577 ordinary shares in issue throughout the period.

 

Diluted profit per share is calculated by adjusting the weighted average number of ordinary shares in issue on the assumption of conversion of dilutive potential ordinary shares, based on the share price at the end of the period. The Company's dilutive potential ordinary shares are shares issued under the Company's Enterprise Management Incentive ('EMI') scheme and options issued under the Company's Unapproved scheme.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR QQLFLLZLZBBD
Date   Source Headline
12th Mar 20247:00 amRNSLaunch of AXIS-CXi Cabinet with AI Software
28th Feb 20242:48 pmRNSResult of AGM
28th Feb 20247:00 amRNSTrading Statement
26th Jan 20241:50 pmRNSHolding(s) in Company
18th Jan 20241:28 pmRNSHolding(s) in Company
11th Jan 20243:06 pmRNSHolding(s) in Company
9th Jan 202412:46 pmRNSNotice of AGM & Posting of Annual Report
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
12th Dec 20237:00 amRNSFinal Results
10th Oct 20237:00 amRNSTrading Update
11th Sep 20237:00 amRNS2023 orders to over 30 countries
4th Jul 20237:00 amRNSHolding(s) in Company
26th Apr 20237:00 amRNSInterim Results
13th Mar 20239:34 amRNSHolding(s) in Company
28th Feb 20233:03 pmRNSResult of AGM
28th Feb 20237:00 amRNSTrading Statement
10th Feb 20231:26 pmRNSHolding(s) in Company
26th Jan 202312:09 pmRNSDirector/PDMR Shareholding
18th Jan 20238:52 amRNSPosting of annual report and notice of AGM
17th Jan 20233:23 pmRNSImage Scan makes first sale of new product
23rd Dec 202211:54 amRNSDirector/PDMR Shareholding
14th Dec 20224:14 pmRNSAppointment of Director
13th Dec 20224:25 pmRNSHolding(s) in Company
13th Dec 20227:00 amRNSFinal Results
9th Dec 20227:00 amRNSNotice of Results
6th Oct 20227:00 amRNSTrading Update
1st Aug 20224:10 pmRNSHolding(s) in Company
25th May 20227:00 amRNSBoard Changes
27th Apr 20227:00 amRNSInterim Results
3rd Mar 20227:00 amRNSNew Industrial Customer
22nd Feb 20223:03 pmRNSResult of AGM
22nd Feb 20227:00 amRNSTrading Statement
20th Jan 202211:53 amRNSPosting of Accounts & AGM Notice
12th Jan 20227:00 amRNSLaunch of new portable X-ray system
10th Dec 20219:05 amRNSInvestor Presentation
7th Dec 202110:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
7th Dec 20217:00 amRNSFinal Results
10th Nov 20211:16 pmRNSAppointed global distributor for Serstech AB
10th Nov 20217:00 amRNSPortable x-ray sale to US Federal Agency
3rd Nov 20217:00 amRNSPre-Close Trading Update
27th Oct 20219:32 amRNSDirector Declaration
13th Sep 20217:00 amRNSTrading Update – New Orders
17th Jun 20217:00 amRNSFirst portable X-Ray sale to Australia
28th Apr 202110:03 amRNSInterim Report - Replacement
28th Apr 20217:00 amRNSNew order
28th Apr 20217:00 amRNSInterim Report
23rd Feb 202111:18 amRNSResult of AGM
22nd Feb 20217:00 amRNSTrading Statement
15th Feb 202111:33 amRNSMello presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.